Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

It is Transgene's second most advanced neoantigen immunotherapy programme after TG4050 for head and neck cancer, which is in ...

Transgene’s therapeutic vaccine candidate TG4001 has flunked a phase 2 solid tumor trial. But, while the prospect failed to ...

Shares of French biotech Transgene (tumbled 13.5% to 1.01 euros by late morning after it announced that its randomized Phase ...

Transgene Biotek Limited is an India-based biotechnology company. The Company is engaged in the research and development of vaccines, oncology and new drug delivery technologies. Its portfolio of ...

Transgene announced that its randomized Phase II study to evaluate TG4001 in combination with avelumab versus avelumab alone in ...

Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to ...

The controversies over regulation of GM crops, the technical ease of tracking, and the availability of grant funds has made transgene flow much easier to study, so it has achieved a higher profile.

Figure 1: Expression of reporter gene constructs derived from the gcy-5, lim-6 and lsy-6 genes. One potential explanation for our observations is that the vector backbone may dictate the packaging ...

双sgRNA系统具有精确和高效编辑的特性，报告RNA富集的RNP系统具有transgene-free、编辑效率高、细胞毒性低、脱靶效应低的特性。因此，利用RE-DSRNP制备 ...

Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer ...

The posters are available on the Posters and Publications page of the Company’s website.